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Inhibition of PI3K-AKT-mTOR Signaling Sensitizes
Melanoma Cells to Cisplatin and Temozolomide
Tobias Sinnberg1,5, Konstantinos Lasithiotakis1,5, Heike Niessner1, Birgit Schittek1, Keith T. Flaherty2,
Dagmar Kulms3, Evelyn Maczey1, Minia Campos4, Jeannette Gogel1, Claus Garbe1 and Friedegund Meier1
In melanoma, the PI3K-AKT-mTOR (AKT) and RAF-MEK-ERK (MAPK) signaling pathways are constitutively
activated and appear to play a role in chemoresistance. Herein, we investigated the effects of pharmacological
AKT and MAPK pathway inhibitors on chemosensitivity of melanoma cells to cisplatin and temozolomide.
Chemosensitivity was tested by examining effects on growth, cell cycle, survival, expression of antiapoptotic
proteins, and invasive tumor growth of melanoma cells in monolayer and organotypic culture, respectively.
MAPK pathway inhibitors did not significantly increase chemosensitivity. AKT pathway inhibitors consistently
enhanced chemosensitivity yielding an absolute increase of cell growth inhibition up to 60% (Po0.05,
combination therapy vs monotherapy with inhibitors or chemotherapeutics). Cotreatment of melanoma cells
with AKT pathway inhibitors and chemotherapeutics led to a 2- to 3-fold increase of apoptosis (Po0.05,
combination therapy vs monotherapy) and completely suppressed invasive tumor growth in organotypic
culture. These effects were associated with suppression of the antiapoptotic Bcl-2 family protein Mcl-1. These
data suggest that inhibition of the PI3K-AKT-mTOR pathway potently increases sensitivity of melanoma cells to
chemotherapy.
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INTRODUCTION
Melanoma is among those malignant tumors whose inci-
dence has increased fastest over the last few decades. The
prognosis for melanoma patients with distant metastases is
dismal, with a median survival time of 6–9 months. In the last
30 years, a large number of chemotherapeutic regimes have
been developed which have, however, failed to lead to a
significant improvement in outcome for patients with
metastatic disease. The alkylating agent dacarbazine, which
acts relatively unselectively on proliferating cells, is con-
sidered to be the reference therapy for metastatic melanoma.
Dacarbazine produced response rates of o10% and median
progression-free survival times of p2 months in recent
studies (Flaherty, 2006) highlighting the urgent need for
new therapeutic approaches. Temozolomide, a closely
related analog of dacarbazine, has comparable clinical
activity, but has the advantages of being orally administered
and of crossing the blood–brain barrier. Other chemothera-
pies, including platinum analogs have demonstrated a similar
level of clinical activity and have been frequently employed
in combination regimens in melanoma (Gogas et al., 2007).
The increasing insight gained into the molecular patho-
genesis of melanoma has brought to light some new,
relatively specific targets for the treatment of metastatic
melanoma. Recent research results show that in malignant
melanoma the RAF-MEK-ERK (MAPK) and PI3K-AKT-mTOR
(AKT) signaling pathways are constitutively activated via
multiple mechanisms (Meier et al., 2005). The MAPK and
AKT signal transduction pathways regulate cell survival,
proliferation and invasion, key functions in the progression of
melanoma. Pharmacologic inhibition of these pathways in
preclinical models support the promise of both the MAPK and
AKT signal transduction pathways as targets for effective
melanoma treatment. In patients, the inhibition of a single
constitutively activated signal pathway appears insufficient to
alter the natural history of the disease (Flaherty, 2006). It has
previously been shown that the constitutive activation of the
MAPK signaling pathway protects tumor cells from apoptosis
and favors the development of a chemoresistant phenotype
(Kolch, 2002). The AKT signal transduction pathway activates
a number of antiapoptotic pathways and also seems to play a
decisive role (Vivanco and Sawyers, 2002; Meier et al.,
2005). Several studies have indicated the potential use of
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inhibitors of the AKT signaling pathway (LY294002, wort-
mannin) for the chemosensitization of human carcinomas
(Brognard et al., 2001; Krystal et al., 2002; Stassi et al., 2005;
Tsurutani et al., 2005). In melanoma, the relative importance
of these pathways in mediating chemotherapy resistance is
unknown. Furthermore, it is not known whether the
mechanism of resistance is similar for different classes of
chemotherapy.
In this study, we inhibited the AKT and MAPK signaling
pathways at different levels in six metastatic melanoma cell
lines and investigated the effects on chemosensitivity to
cisplatin and temozolomide.
RESULTS
The AKT pathway inhibitors LY294002, wortmannin, and
rapamycin and the MAPK pathway inhibitors sorafenib, U0126,
and PD98059 inhibit the AKT and MAPK signaling pathways,
respectively
The efficacy of the AKT (LY294002, wortmannin, rapamycin)
and MAPK (sorafenib, U0126, PD98059) pathway inhibitors
was verified by Western blot analysis of cell lysates from
metastatic melanoma cells (451Lu, SKMel28) for phosphory-
lated AKT, p70S6K (ribosomal protein S6 kinase which is
phosphorylated by mTOR) and ERK. Cells were treated with
inhibitors for 6 hours before cell lysis. The mTOR inhibitor
rapamycin (10 nM) effectively inhibited phosphorylation of
p70S6K (Figure 1a). The PI3K inhibitors LY294002 (30 mM)
and wortmannin (4 mM) were effective in inhibition of
phosphorylation of AKT and p70S6K. The multikinase
inhibitor sorafenib targeting BRAF and other kinases (4 mM)
and the MEK inhibitors U0126 (30 mM) and PD98059 (50 mM)
effectively inhibited phosphorylation of ERK.
It has been reported that cisplatin induces AKT activation
thus attenuating cisplatin-induced apoptosis (Belyanskaya
et al., 2005; Winograd-Katz and Levitzki, 2006). To
investigate whether the chemotherapeutic agents cisplatin
and temozolomide affect AKT or MAPK signaling, metastatic
melanoma cells were treated with increasing concentrations
of cisplatin or temozolomide for 8 hours before cell lysis.
Phosphorylated AKT, p70S6K, and ERK were determined by
Western blot analysis. As shown in Figure 1b neither cisplatin
nor temozolomide increased phosphorylation of AKT,
p70S6K, or ERK.
The AKT pathway inhibitors LY294002, wortmannin, and
rapamycin combined with cisplatin or temozolomide significantly
inhibit growth of melanoma cells in monolayer culture
The effects of signaling inhibitors and chemotherapeutic
agents alone or in combination on melanoma cell growth in
monolayer culture after 72 hours treatment were determined
by a fluorimetric assay (Figure 2d and e). First dose and time
kinetic studies with signaling inhibitors (rapamycin,
LY294002, wortmannin; sorafenib, U0126, PD98059) and
chemotherapeutic agents (cisplatin, temozolomide) in six
metastatic melanoma cell lines (451Lu, SKMel28, 1205Lu,
WM852, SKMel19, Mewo) were done (examples are shown
in Figure 2a and b), and the impact of cell density on growth
assay data was assessed (an example is shown in Figure 2c).
Both the mTOR inhibitor rapamycin and the PI3K inhibitor
wortmannin as monotherapy did not or only slightly affect
melanoma cell growth. The percent growth inhibition of cells
treated with rapamycin (10 nM) ranged from 11.1±0.7
(SKMel19) to 20.4±1.5% (451Lu). The inhibition rates
yielded by wortmannin (4 mM) in different cell lines ranged
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Figure 1. AKT and MAPK pathway inhibitors, but not chemotherapeutic
agents, affect the AKT and MAPK signaling pathways, respectively.
(a) Western Blot analyses of cell lysates from metastatic melanoma cells
(SKMel28) after 6 hours treatment with culture medium containing 10% FBS
without or with DMSO as controls, the mTOR inhibitor rapamycin, the PI3K
inhibitors LY294002 or wortmannin, the multikinase inhibitor sorafenib, and
the MEK inhibitors U0126 or PD98059 for phosphorylated and total AKT,
ERK, and p70S6K. Equal loading was monitored with antibodies against AKT,
ERK, and b-Actin. (b) Western Blot analyses of cell lysates from metastatic
melanoma cells (SKMel28, 451Lu) after 8 hours treatment with increasing
concentrations of cisplatin or temozolomide for phosphorylated and total
AKT, ERK, and p70S6K.
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from 1.3±1.6 (451Lu) to 14±3.4% (WM852). On the
contrary, the PI3K inhibitor LY294002 (30 mM) decreased
growth of most melanoma cell lines tested with inhibition
rates ranging from 28.5±4.5 (SKMel28) to 55.1±4.1%
(1205Lu). The growth inhibitory effects of the multikinase
inhibitor sorafenib (4 mM) significantly varied among the
different cell lines tested. 451Lu, 1205Lu, and WM852 cells
appeared to be more sensitive to sorafenib with inhibition
rates of 67.4±3.9, 80.8±9.3, and 54.6±9.7%, respectively,
whereas SKMel28, SKMel19, and Mewo cells were more
resistant to sorafenib with inhibition rates of 20.1±5.6,
19.9±4.4, and 21.1±4.9%, respectively. MEK inhibitor
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Figure 2. The AKT pathway inhibitors LY294002, wortmannin, and rapamycin combined with cisplatin or temozolomide significantly inhibit melanoma cell
growth. Growth assay of six metastatic melanoma cell lines (451Lu, 1205Lu, WM852, SKMel28, SKMel19, Mewo) in monolayer culture using a fluorimetric
assay with 4-methylumbelliferyl heptanoate (MUH). (a, b) Dose and time kinetic studies (example): Cells were treated with increasing concentrations of
rapamycin or temozolomide (TMZ) for 24, 48, and 72 hours. The percentage of growth inhibition compared to DMSO-treated controls is shown on the y axis
(*Po0.05). Rapamycin alone did not significantly inhibit melanoma cell growth. TMZ differently affected melanoma cell growth depending on the cell line
tested. At lower concentrations achieved in vivo TMZ did not yield significant growth inhibition. Maximal growth inhibitory effects were observed after 72 hours
treatment. (c) Cell density studies (example): 451Lu cells were seeded in 96-well plates at the indicated densities and treated with increasing concentrations of
temozolomide (TMZ) for 72 hours. The percentage of growth inhibition compared to DMSO-treated controls is shown on the y axis. No significant differences
between cell densities in susceptibility toward growth inhibition by TMZ is observed. (d, e) Cells were treated with signaling inhibitors (rapamycin (rap),
LY294002 (LY), wortmannin (wortm); sorafenib (Soraf), U0126, PD98059 (PD), or/and chemotherapeutics (cisplatin; TMZ) at the indicated concentrations for
72 hours. The percentage of growth inhibition compared to DMSO-treated controls is shown on the y axis. Combinations of AKT pathway inhibitors (rapamycin,
LY294002, wortmannin) but not of MAPK pathway inhibitors (sorafenib, U0126, PD98059) with cisplatin or even more temozolomide significantly increased
growth inhibition in all metastatic melanoma cell lines tested (*Po0.05 compared with inhibitor or chemotherapeutic alone). (f) Response surface analysis of the
metastatic melanoma cell lines 451Lu, SKMel28, SKMel19, and Mewo treated with the combination of rapamycin and temozolomide. The effects of drug
combinations (z axis) were plotted against the concentrations of the single drugs (x- and y axes). The surface shown represents the additive growth inhibitory
effects for the combination of rapamycin and temozolomide as calculated from the dose-response curves for the single drugs. The effects of the drug
combinations tested (þ ) are positioned above the surface of additivity, i.e., the effects of combination treatment with rapamycin and temozolomide are
superadditive. (g) 451Lu and SKMel28 cells were treated with a BRAF-specific siRNA (BRAF) or with a control scrambled siRNA (scr) as indicated. After 72 hours,
cell extracts were prepared and blotted for total BRAF and p-ERK detection as indicated. b-Actin served as loading control. (h) 451Lu and SKMel28 cells were
treated with a control scrambled siRNA, a BRAF-specific siRNA, and combinations of scrambled siRNA or BRAF siRNA with cisplatin or temozolomide at the
indicated concentrations for 72 hours. The percentage of growth inhibition compared to scrambled siRNA-treated controls is shown on the y axis.
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U0126 reduced growth of most melanoma cell lines with
inhibition rates ranging from 28±6.1 (Mewo) to 66.4±6.7%
(1205Lu). MEK inhibitor PD98059 reduced growth of
melanoma cell lines to a lesser degree compared with
U0126 with inhibition rates ranging from 20.5±8.5 (Mewo)
to 49.3±9.8% (451Lu). Cisplatin and temozolomide pro-
duced diverse effects on growth of the different melanoma
cell lines. Most melanoma cell lines displayed modest
chemosensitivity to cisplatin (6 mM) with inhibition rates
ranging from 16±5.2 (SKMel28) to 55.1±1.2% (Mewo).
Percent inhibition yielded by 300mM temozolomide was
lower compared with cisplatin and ranged from 10.1±4.2
(451Lu) to 37.4±0.9% (SKMel19).
Intriguingly, combinations of AKT pathway inhibitors
(rapamycin, LY294002, wortmannin) with cisplatin or temo-
zolomide significantly increased growth inhibition in all
metastatic melanoma cell lines tested compared with AKT
pathway inhibitors or chemotherapeutics alone. The increase
in growth inhibition was most pronounced with combina-
tions of AKT pathway inhibitors and temozolomide. The
absolute increase in growth inhibition yielded by the
combination of LY294002 (30 mM) with temozolomide
(300 mM) ranged from 14 (Mewo) to 35% (WM852; Po0.05,
combination treatment vs monotherapy with LY204002 or
temozolomide). The absolute increase in growth inhibition
yielded by the combination of wortmannin (4 mM) with
temozolomide (300mM) ranged from 29 (SKMel28) to 55%
(1205Lu; Po0.05, combination treatment vs monotherapy
with wortmannin or temozolomide). The absolute increase of
growth inhibition yielded by the combination of temozolo-
mide (300 mM) with rapamycin (10 nM) ranged from 17
(SKMel28) to 60% (WM852; Po0.05, combination treatment
vs monotherapy with rapamycin or temozolomide). Likewise,
the combination of LY294002 (30 mM) with cisplatin (6 mM)
yielded an absolute increase of growth inhibition ranging
from 17 (1205Lu) to 34% (451Lu; Po0.05, combination
treatment vs monotherapy with LY204002 or cisplatin).
Wortmannin (4 mM) combined with cisplatin (6mM) yielded
an increase of growth inhibition ranging from 12 (451Lu) to
36% (SKMel28; Po0.05, combination treatment vs mono-
therapy with wortmannin or cisplatin). Rapamycin (10 nM)
combined with cisplatin (6 mM) yielded an absolute increase
of growth inhibition ranging from 9 (WM852) to 60% (451Lu;
Po0.05, combination treatment vs monotherapy with
rapamycin or cisplatin). By contrast, combinations of MAPK
pathway inhibitors (sorafenib, U0126, PD98059) with
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Figure 2. Continued.
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Figure 2. Continued.
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cisplatin or temozolomide did not yield additional growth
inhibition in virtually all melanoma cell lines tested
(P40.05).
To assess whether combinations of AKT pathway inhibi-
tors and chemotherapeutic agents inhibit melanoma cell
growth in an additive or synergistic fashion, a response
surface analysis (Tallarida, 2000) of six metastatic melanoma
cell lines (451Lu, 1205Lu, WM852, SKMel28, SKMel19,
Mewo) after 72 hours treatment with combinations of the
mTOR inhibitor rapamycin or the PI3K inhibitor wortmannin
and the chemotherapeutic agent temozolomide was per-
formed. Figure 2f illustrates that the effects of all tested
combinations of rapamycin and temozolomide are posi-
tioned above the surface of additivity, that is, the effects of
combination treatment of melanoma cells with rapamycin
and temozolomide are superadditive or synergistic. Table 1
illustrates that combinations of rapamycin and temozolomide
exert a potentiating effect on melanoma cells compared to
the expected additive effect. The maximal effects of the
combination treatment are clearly increased compared to the
effects seen with single drug treatment. Similar synergistic
effects were observed with combinations of the PI3K inhibitor
wortmannin and temozolomide (data not shown).
We observed that combination of pharmacological MAPK
pathway inhibitors such as sorafenib with chemotherapeutics
does not result in additional growth inhibition. To further
investigate the effect of MAPK pathway inhibition on
chemosensitivity of melanoma cells 451Lu and SKMel28
cells were treated with a BRAF-specific small interfering RNA
(BRAF siRNA), a control scrambled siRNA, the chemother-
apeutic agents cisplatin, or temozolomide and combinations
of siRNA and chemotherapeutics, and subjected to the
growth assay described above. BRAF siRNA reduced BRAF
and p-ERK in transfected melanoma cells (Figure 2g).
Melanoma cell growth (Figure 2h) was not or only slightly
affected by control siRNA, BRAF siRNA, or chemotherapeutic
agents with control siRNA. Combination of cisplatin with
BRAF siRNA yielded an increase of growth inhibition
ranging from 14 (451Lu) to 19% (SKMel28) compared to
control siRNA. Likewise, the combination of temozolomide
with BRAF siRNA yielded an increase of growth inhibition
ranging from 15 (451Lu) to 9% (SKMel28) compared to
control siRNA. However, growth inhibition did not
exceed 38 and 23% in melanoma cells treated with BRAF
siRNA in combination with cisplatin and temozolomide,
respectively.
AKT pathway inhibitors combined with cisplatin or
temozolomide potently induce apoptosis of melanoma cells in
monolayer culture
For the following studies the PI3K inhibitor LY294002 and the
mTOR inhibitor rapamycin, which inhibit the PI3K-AKT-
mTOR (AKT) pathway upstream and downstream, respec-
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Figure 2. Continued.
Table 1. Potentiating factors and maximal effects of
combination treatment of melanoma cells with
rapamycin and temozolomide
Melanoma
cell line
Potentiating factor1
(mean±SD) Emax(combi)
2
451Lu 1.89±0.48 +
1205Lu 2.41±0.32 +
WM852 3.33±0.33 ++
SKMel28 2.98±0.09 +
SKMel19 2.99±0.87 ++
Mewo 2.12±0.14 ++
1Potentiating factor=Effectcombination/Effectadditive. Effect of drug combina-
tion compared to the expected additive effect of drug combination.
2Emax(combi)=maximal effect of drug combination.
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tively, were selected. To investigate whether the mTOR
inhibitor rapamycin, the PI3K inhibitor LY294002, cisplatin,
and temozolomide alone or in combination affect the cell
cycle, metastatic melanoma cells (SKMel28, 451Lu) were
treated with DMSO as control, rapamycin, LY294002,
cisplatin, temozolomide, or combinations of inhibitors with
chemotherapeutics for 72 hours. Subsequently cell-cycle
distribution was analyzed by flow cytometry (Figure 3a
and b). Cells treated with the mTOR inhibitor rapamycin did
not undergo any appreciable cell-cycle arrest. LY294002
increased the percentage of cells in the sub-G1 (apoptotic)
cell fraction to 11.6±3.5% in 451Lu and 12.1±3.0% in
SKMel28 cells whereas rapamycin did not or did only
marginally increase the sub-G1 fraction (o5% in both cell
lines). Monochemotherapy with cisplatin induced G2 arrest
and increased the apoptotic cell fraction to 13.6±0.4 and
16±2.0% in 451Lu and SKMel28 cells, respectively.
Temozolomide did not appear to affect cell cycle or survival
of melanoma cells (sub-G1 fraction o5% in both cell lines).
Combination of rapamycin with cisplatin increased the
apoptotic fraction to 28.3±1.7 and 28.3±5.5% in 451Lu
and SKMel28 cells, respectively (Po0.05 compared with
rapamycin or cisplatin). Combination of LY294002 with
cisplatin increased the apoptotic fraction to 36±4.1 and
30.3±2.8% in 451Lu and SKMel28 cells, respectively
(Po0.05 compared with LY204002 or cisplatin). Likewise,
combination of rapamycin with temozolomide increased the
apoptotic cell fraction to 22.0±4.3 and 26.2±3.15% in
451Lu and SKMel28 cells, respectively (Po0.05 compared
with rapamycin or temozolomide). Combination of
LY294992 with temozolomide increased the apoptotic cell
fraction to 22.2±4.6 and 32.9±3.5% in 451Lu and SKMel28
cells, respectively (Po0.05 compared with LY292002 or
temozolomide).
To confirm that the mTOR inhibitor rapamycin and the
PI3K inhibitor LY294002 combined with cisplatin or temo-
zolomide induce significant apoptosis in melanoma cells,
metastatic melanoma cells were treated with DMSO as
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Figure 3. AKT pathway inhibitors combined with cisplatin or temozolomide potently induce melanoma cell apoptosis. (a, b) Cell-cycle distribution of
metastatic melanoma cells (451Lu, SKMel28) after 72 hours treatment with DMSO as control, rapamycin 10 nM (Rapa), LY294002 30mM (LY), cisplatin 6 mM (CP),
temozolomide 300mM (TMZ), or combinations of inhibitors with chemotherapeutics. Coadministration of inhibitors with chemotherapeutics significantly
increased the percentage of apoptotic melanoma cells compared with inhibitors or chemotherapeutics alone. Results are expressed as mean±SD values of three
independent experiments. (c, d) Internucleosomal DNA fragmentation of metastatic melanoma cells (451Lu, SKMel28) 72 hours after treatment with culture
medium plus DMSO as control, rapamycin 10 nM (Rapa), LY294002 30 mM (LY), cisplatin 6 mM (CP), temozolomide 300 mM (TMZ), or combinations of inhibitors
with chemotherapeutics. Internucleosomal DNA fragmentation was quantified by assaying for cytoplasmic mononucleosome- and oligonucleosome-associated
histone using a cell death detection ELISA kit. The rate of apoptosis is reflected by the enrichment of nucleosomes in the cytoplasm and is expressed as
mean±SD of triplicates. Rapamycin or LY294002 combined with cisplatin or temozolomide potently increased the rate of apoptotic melanoma cells. (*Po0.05
compared with CP or LY alone; zPo0.05 compared with TMZ or LY alone).
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control, rapamycin, LY294002, cisplatin, temozolomide, or
combinations of inhibitors with chemotherapeutics. After
72 hours cells were subjected to a cell death detection ELISA
(Figure 3c and d). Combination treatment of metastatic
melanoma cells with signaling inhibitors (rapamycin 10 nM,
LY294002 30 mM) plus chemotherapeutics (cisplatin 6 mM,
temozolomide 300mM) potently increased the rate of apopto-
tic melanoma cells compared to treatment with signaling
inhibitors or chemotherapeutics alone (Po0.05 compared
with inhibitors or chemotherapeutics).
AKT pathway inhibitors combined with cisplatin or
temozolomide abolish invasive tumor growth of melanoma cells
in organotypic culture
To validate the data obtained with monolayer cultures in a
near physiologic context, metastatic melanoma cells were
incorporated into human dermal reconstructs and were
treated with DMSO as control, the PI3K inhibitor
LY294002, the mTOR inhibitor rapamycin, cisplatin, and
temozolomide alone or in combination (Figure 4a–d).
Control-treated metastatic melanoma cells exhibited aggres-
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Figure 4. AKT pathway inhibitors combined with cisplatin or temozolomide abrogate invasive tumor growth of melanoma cells in organotypic culture. (a and
b) Metastatic melanoma cells (451Lu) grown in human dermal reconstructs were treated with culture medium plus DMSO as control, the PI3K inhibitor
LY294002 (30 mM), the mTOR inhibitor rapamycin (10 nM), cisplatin (3 mM), temozolomide (300 mM), or combinations of LY294002 plus cisplatin and rapamycin
plus temozolomide, and were stained with hematoxylin (HE). Arrows indicate unaffected fibroblasts showing the typical fibroblast morphology. Scale
bar¼ 25 mm. (c and d) 451Lu melanoma cells in dermal reconstructs after control treatment (DMSO) or treatment with inhibitor (LY294002, rapamycin) or/and
chemotherapeutic agent (cisplatin, temozolomide) were counted. Meanþ SD of direct counting of 6 high-powered fields are depicted (*Po0.05 compared with
inhibitor or chemotherapeutic agent alone). (e) Cell-cycle distribution of human fibroblasts treated with rapamycin 10 nM (Rapa), LY294002 30 mM (LY), cisplatin
6mM (CP), temozolomide 300mM (TMZ), or combinations of inhibitors with chemotherapeutics for 72 hours. (f) Cell death detection ELISA of fibroblasts 72 hours
after treatment with signaling inhibitors (10 nm rapamycin, Rapa; 30mM LY294002, LY) or/and chemotherapeutic agents (300 mM temozolomide, TMZ; 6 mM
cisplatin, CP).
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sive invasive growth of tumor cell clusters and nests in the
dermis. The PI3K inhibitor LY294002 reduced number and
size of tumor cell nests to small melanoma cell nests
and single melanoma cells scattered throughout the dermis.
The mTOR inhibitor rapamycin reduced size of tumor cell
nests in the dermis. Monochemotherapy with cisplatin at 3 mM
and temozolomide at 300 mM did not significantly affect
invasive melanoma growth. When increasing the dosages
cisplatin at 6 mM slightly reduced number and size of
melanoma cell nests in the dermis whereas temozolomide
at 500mM did not appear to affect invasive melanoma growth
(data not shown). Interestingly, coadministration of the PI3K
inhibitor LY294002 or the mTOR inhibitor rapamycin with
cisplatin or temozolomide completely suppressed invasive
tumor growth with very few rounded melanoma cells left in
the dermis. In Figure 4, representative data for 451Lu
metastatic melanoma cells treated with cisplatin plus
LY294002 (Figure 4a and c) and temozolomide plus
rapamycin (Figure 4b and d), respectively, are presented.
Similar results were obtained for 451Lu cells treated with
cisplatin plus rapamycin and temozolomide plus LY294002
(data not shown).
Of significance, nontumor-derived cells of human skin such
as fibroblasts did not appear to undergo apoptosis (Figure 4a
and b). This observation was further investigated by propidium
iodide staining and fluorocytometric analysis of cell cycle of
human fibroblasts (Figure 4e). Cells treated with rapamycin
(10nM) or temozolomide (300mM) alone did not undergo any
appreciable cell-cycle arrest compared with DMSO-treated
controls. Treatment of fibroblasts with cisplatin (6mM) caused
G2 arrest but did not increase the apoptotic (sub-G1) fraction,
whereas the PI3K inhibitor LY294002 (30mM) slightly increased
the apoptotic fraction (o10%). Combined treatment of
rapamycin or LY294002 with cisplatin or temozolomide did
not cause further increase in the apoptotic fraction of cells
compared with monotherapy. To further confirm this observa-
tion cell death detection ELISA was performed (Figure 4f).
Treatment of fibroblasts with signaling inhibitors (10nm
rapamycin, 30mM LY294002) or chemotherapeutic agents
(300mM temozolomide, 6mM cisplatin) alone did not affect
survival. Fibroblasts treated with combinations of rapamycin
with cisplatin or temozolomide were also not affected.
Combinations of LY294002 with cisplatin or temozolomide
slightly increased the apoptotic rate of fibroblasts.
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Figure 5. AKT pathway inhibitors combined with cisplatin or temozolomide suppress the antiapoptotic Bcl-2 family protein Mcl-1. (a) Metastatic melanoma
cells (451Lu, SKMel28) were treated with culture medium without or with DMSO as control, the mTOR inhibitor rapamycin 10 nM (rapa), the PI3K inhibitor
LY294002 30mM (LY), cisplatin 6 mM, temozolomide 300mM (TMZ), or combinations of inhibitors with chemotherapeutics for 24 hours. Protein levels of Mcl-1,
Bcl-2 and Bcl-xL were determined by Western blot analysis. (b) Following treatment of metastatic melanoma cells (451Lu) with rapamycin 10 nM (Rapa),
LY294002 30 mM (LY), cisplatin 6 mM (CP), temozolomide 300 mM (TMZ), or combinations of inhibitors with chemotherapeutics for 24–48 hours, RNA was isolated
and subjected to quantitative RT-PCR using Mcl-1 and actin primers. (c) Western blot analysis of metastatic melanoma cells (451Lu, SKMel28) 24 hours after
treatment with the MEK inhibitor PD98059 50 mM (PD), the PI3K inhibitor LY294002 30 mM (LY), cisplatin 6 mM (CP), temozolomide 300mM (TMZ), or
combinations of inhibitors with chemotherapeutics.
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AKT pathway inhibitors combined with cisplatin or
temozolomide suppress the antiapoptotic Bcl-2 family
protein Mcl-1
In melanoma, the expression of the antiapoptotic B-cell
lymphoma-2 (Bcl-2) family proteins Bcl-2, Bcl-xL and
myeloid cell leukemia-1 (Mcl-1) increase with progression
and may be involved in resistance to conventional therapies
(Bush and Li, 2003; Zhang and Rosdahl, 2006). Thus, the
striking effects of coexposure of melanoma cells to AKT
pathway inhibitors and chemotherapeutics were examined in
relation to expression of Bcl-2, Bcl-xL, and Mcl-1 by Western
blot analysis (Figure 5a). Exposure of metastatic melanoma
cells to the mTOR inhibitor rapamycin individually did not
alter protein levels of Mcl-1, Bcl-2, or Bcl-xL whereas the
PI3K inhibitor LY294002 reduced Mcl-1 and Bcl-2 levels.
Neither cisplatin nor temozolomide affected antiapoptotic
protein levels. Combinations of LY294002 with cisplatin or
temozolomide further decreased levels of Bcl-2, in particular
in 451Lu cells. Strikingly, coadministration of rapamycin or
LY294002 with cisplatin or temozolomide nearly eliminated
Mcl-1.
To determine whether Mcl-1 is downregulated at the
transcriptional level, Mcl-1 mRNA levels were examined by
quantitative RT-PCR in metastatic melanoma cells exposed to
AKT pathway inhibitors (rapamycin, LY294002) or/and
chemotherapeutic agents (cisplatin, temozolomide; Figure
5b). The results indicate that Mcl-1 mRNA levels were not
downregulated.
To examine whether MAPK pathway inhibitors without or
with chemotherapeutic agents affect Mcl-1 levels metastatic
melanoma cells treated with the MEK inhibitor PD98059
(50 mM) alone or in combination with cisplatin (6mM) or
temozolomide (300 mM) were subjected to Western blot
analysis for Mcl-1 (Figure 5c). Melanoma cells treated with
the PI3K inhibitor LY294002 without or with chemother-
apeutic agents served as positive controls. In contrast to the
PI3K inhibitor LY294002, the MEK inhibitor PD98059 alone
or combined with cisplatin or temozolomide did not suppress
Mcl-1 levels.
DISCUSSION
We examined whether targeting the PI3K-AKT-mTOR (AKT)
or the RAF-MEK-ERK (MAPK) pathway, which are both
constitutively activated in melanoma and appear to play a
relevant role in tumor chemoresistance, would efficiently
enhance melanoma chemosensitivity. In particular, we
investigated the effects of the AKT pathway inhibitors
LY294002, wortmannin, and rapamycin and the MAPK
pathway inhibitors sorafenib, U0126, and PD98059 on
chemosensitivity of six metastatic melanoma cell lines to
cisplatin and temozolomide. The AKT pathway inhibitors
significantly increased the growth inhibitory effects of
cisplatin and temozolomide whereas the MAPK pathway
inhibitors did not enhance chemosensitivity. Moreover,
combinations of the PI3K inhibitor LY294002 or the mTOR
inhibitor rapamycin with the chemotherapeutics cisplatin or
temozolomide significantly induced apoptosis of
melanoma cells in monolayer culture and completely
suppressed invasive tumor growth of melanoma cells in
organotypic culture. These effects were associated with
nearly complete abolishment of the antiapoptotic Bcl-2
family protein Mcl-1.
Recent studies suggest that anticancer agents can trigger
prosurvival events that attenuate their therapeutic efficacy. In
particular, cisplatin has been shown to induce activation of
the AKT pathway and to attenuate cisplatin-induced apopto-
sis in several human cancer cell lines; moreover inhibition of
AKT activity sensitized cells to cisplatin (Belyanskaya et al.,
2005; Ohta et al., 2006; Winograd-Katz and Levitzki, 2006).
In our study, treatment of melanoma cells with cisplatin or
temozolomide did not increase activation of AKT or MAPK
pathway. However, both the AKT and the MAPK pathway,
reported to be relevant for tumor cell survival and drug
resistance, are constitutively activated in melanoma through
multiple mechanisms such as adhesion receptor signaling,
autocrine and paracrine growth factors, loss of negative
regulators (PTEN, phosphatase and tensin homologue deleted
from chromosome 10), and activating mutations (NRAS,
BRAF; Meier et al., 2005). Thus, both AKT and MAPK
inhibition may be potent to enhance melanoma chemosensi-
tivity.
Previous studies demonstrated that rapamycin inhibiting
mTOR and thus p70S6K prevents the serine phosphorylation
of insulin receptor substrate-1 thus promoting its tyrosine
phosphorylation and subsequently PI3K activation, that is,
rapamycin may activate PI3K and thus attenuate its ther-
apeutic effects (O’Reilly et al., 2006). In our study, however,
rapamycin did not appear to enhance AKT phosphorylation
(Figure 1a).
The effects of MAPK or AKT pathway inhibitors alone on
melanoma cell growth varied among the different cell lines
tested. In particular, the multikinase inhibitor sorafenib and
the PI3K inhibitor LY294002 produced variable growth
inhibitory effects. Notably, sensitivity to sorafenib and
LY294002 appeared to be independent from the status of
BRAF and PTEN, respectively (data not shown). Data
accumulate, suggesting that signaling inhibitors such as
sorafenib and LY294002 may also exert their antitumor
effects through their impacts on targets other than BRAF and
PI3K, respectively. Indeed, sorafenib was identified during a
large medicinal chemistry optimization program, and this
compound was selected for further pharmacological char-
acterization based on its potent inhibition of Raf kinase and
its favorable kinase selectivity profile. However, it does not
appear to be a specific RAF kinase inhibitor as it has been
reported to inhibit other proteins such as vascular endothelial
growth factor receptor-2 and -3, platelet-derived growth
factor receptor-b, Flt-3, and c-KIT (Wilhelm et al., 2004).
Also, LY294002 does not only have a broad inhibitory profile
across different classes of PI3Ks but also inhibits mTOR,
DNA-dependent protein kinase, casein kinase 2 and Pim-1
(Gharbi et al., 2007). Furthermore, other PI3K-independent
effects of LY294002 have been reported. For example,
LY294002 inhibits calcium signaling (Tolloczko et al.,
2004) and transcription factors such as NF-kB (Kim et al.,
2005).
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Monochemotherapy with cisplatin or temozolomide failed
to yield efficient growth inhibition in most metastatic
melanoma cell lines tested. However, AKT pathway inhibi-
tors, that is, the PI3K inhibitors LY294002 and wortmannin
and the mTOR inhibitor rapamycin, significantly augmented
growth inhibition of cisplatin and temozolomide in all cell
lines tested. Moreover, response surface analysis of melano-
ma cells treated with combinations of rapamycin or
wortmannin and temozolomide revealed a synergistic effect.
By contrast, combinations of MAPK pathway inhibitors, that
is, the multikinase inhibitor sorafenib and the MEK inhibitors
PD98059 and U0126, with chemotherapeutics did not
achieve additional growth inhibition. Furthermore, BRAF
depletion by BRAF siRNA did not efficiently enhance growth
inhibition of chemotherapeutics compared to AKT pathway
inhibitors. It could be argued that additional growth inhibi-
tion by the multikinase inhibitor sorafenib and the MEK
inhibitors PD98059 and U0126 is not achieved because
these inhibitors on their own potently inhibit growth of
sensitive melanoma cell lines. Indeed, sorafenib has been
reported to inhibit DNA synthesis of melanoma cells more
effectively than BRAF siRNA (Karasarides et al., 2004). It is
possible that the degradation of BRAF protein occurs more
slowly than its inhibition by a small molecular inhibitor.
Furthermore, targeting several kinases with sorafenib may
produce a more potent effect than targeting a single kinase
with siRNA. However, use of sorafenib as a single agent in
patients with metastatic melanoma failed to provide sig-
nificant clinical benefit (Eisen et al., 2006). Interestingly, in
our previous experimental studies (Meier et al., 2007;
Lasithiotakis et al., 2008) we observed that sorafenib
decreases but does not efficiently suppress tumor growth of
451Lu metastatic melanoma cells in organotypic culture
suggesting that assessment of melanoma growth in organo-
typic culture may serve as a predictor for clinical benefit.
Moreover, our observation that combinations of PI3K/AKT/
mTOR inhibitors with cisplatin or temozolomide abrogate
melanoma growth in organotypic culture argues for the
development of combination therapies using PI3K/AKT/
mTOR inhibitors together with cisplatin or temozolomide.
This hypothesis is supported by recent in vivo studies
demonstrating that in melanoma the mTOR inhibitor
CCI-779 increases the chemotherapeutic efficacy of cisplatin
and dacarbazine in a SCID mouse xenotransplantation model
(Thallinger et al., 2007a, b). However, we should take into
account that most of the signaling inhibitors are not specific
and that further studies using siRNA are required to confirm
this hypothesis and to elucidate the mechanisms of action of
these drugs. Interestingly, a previous in vitro study (Mirmo-
hammadsadegh et al., 2007) demonstrated that treatment of
melanoma cell lines (BLM, MV3, M13, A375) with cisplatin
increased p-ERK and enhanced chemoresistance through
activation of the cell survival protein RSK1 (90 kDa ribosomal
S6 kinase). The MEK inhibitor U0126 was able to block this
effect and sensitized cells to cisplatin-induced apoptosis. One
explanation for this discrepancy might be the different
melanoma cell lines investigated. Of note, recent data
suggest that the chemosensitizing effects of MAPK and
AKT pathway inhibitors may depend on the classes of
chemotherapeutic agents. For example, MCP110, which
inhibits RAS-induced activation of the RAF-MEK-ERK path-
way, has been shown to synergize with multiple chemother-
apeutics targeting the microtubule network (Skobeleva et al.,
2007).
In our study, combinations of the PI3K inhibitor LY294002
or the mTOR inhibitor rapamycin with the chemotherapeu-
tics cisplatin or temozolomide nearly completely extin-
guished the antiapoptotic Bcl-2 family protein Mcl-1. Mcl-1
is thought to protect cells from a variety of proapoptotic
stimuli that activate the mitochondrial apoptotic pathway and
has been implicated in resistance to anticancer drugs (Craig,
2002). Interestingly, Mcl-1 is upregulated by the AKT
pathway through a transcription factor complex containing
cAMP response element-binding protein (Wang et al., 1999).
In melanoma, therefore, constitutive activation of the PI3K-
AKT-mTOR pathway may contribute to upregulation of Mcl-1
and chemoresistance. Thus, inhibition of PI3K-AKT-mTOR
signaling may downmodulate Mcl-1 and enhance melanoma
chemosensitivity. Indeed, data accumulate, suggesting that
targeting Mcl-1 may be particularly effective in sensitizing
melanoma cells to anticancer agents (Hersey, 2006). A recent
immunohistochemical study demonstrated that Mcl-1 ex-
pression is associated with melanoma progression (Zhuang
et al., 2007). Inactivation of Bcl-2, Bcl-xL, or Mcl-1 by shRNA
was recently shown to enhance the sensitivity of melanoma
cells to the MEK inhibitor U0126. Interestingly, the most
effective cytotoxic effect was found after inactivating Mcl-1
(Verhaegen et al., 2006). Wang et al. (2007) confirmed that
Mcl-1 is critical for apoptosis induction by U0126 as siRNA
knockdown of Mcl-1 increased apoptosis particularly in the
apoptosis-resistant melanoma cell lines. Also, the survival of
bortezomib-treated melanoma cells was found to rely
primarily on Mcl-1 using a specific RNA interference
approach (Wolter et al., 2007). Furthermore, in melanoma,
cisplatin-induced apoptosis was shown to be associated with
decreased Mcl-1 levels (Bowen et al., 2003). Moreover, Mcl-
1 antisense therapy was shown to chemosensitize human
melanoma to dacarbazine in a SCID mouse xenotransplanta-
tion model (Thallinger et al., 2003). Interestingly, AKT
pathway inhibitors or/and chemotherapeutic agents did not
induce downregulation of Mcl-1 mRNA levels monitored by
quantitative RT-PCR suggesting that the decrease in Mcl-1
protein levels observed with combinations of AKT pathway
inhibitors and chemotherapeutic agents is the result of a
translational or posttranslational mechanism. One may
speculate that apoptosis induction in melanoma cells by
combinations of AKT pathway inhibitors and chemothera-
peutic agents involves down-regulation of Mcl-1 through
inhibition of mTOR-regulated protein translation. Indeed,
previous studies report that the Mcl-1 protein level in
dendritic cells is tightly regulated by GM-CSF signaling via
PI3K and mTOR. Despite the large decrease in the Mcl-1
protein level following treatment with rapamycin or
LY294002, no significant decrease in the Mcl-1 mRNA level
was observed (Woltman et al., 2003). Accordingly, Mcl-1
appears to be a crucial player in mediating chemoresistance
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in melanoma, a phenomenon that may be overcome by
coapplication of PI3K-AKT-mTOR pathway inhibitors as
suggested by our study. However, the mechanisms by which
the PI3K inhibitor LY294002 and the mTOR inhibitor
rapamycin cooperate with chemotherapeutics such as
cisplatin and temozolomide to achieve efficient suppression
of antiapoptotic Mcl-1 protein are unclear and deserve
further study.
In summary, our data suggest that inhibition of the PI3K-
AKT-mTOR signaling pathway potently increases sensitivity
of melanoma cells to chemotherapy. The PI3K inhibitor
LY294002 and the mTOR inhibitor rapamycin in combina-
tion with cisplatin or temozolomide may exert their
proapoptotic effects, at least in part through suppression of
the antiapoptotic Bcl-2 family protein Mcl-1.
MATERIALS AND METHODS
Isolation and culture of human cells
The clinical ethics committee of the university hospital of Tuebingen
approved all described studies. The studies were conducted
according to Declaration of Helsinki Principles. Patients gave their
written informed consent. Human metastatic melanoma cells
(451Lu, SKMel28, 1205Lu, WM852, SKMel19, Mewo) were cultured
in RPMI 1640 medium supplemented with 10% fetal bovine serum
(FBS), penicillin, and streptomycin. Fibroblasts were isolated from
human foreskin after routine circumcision. Samples were stored at
4 1C in Hank’s balanced salt solution without Ca2þ or Mg2þ
containing penicillin, gentamycin, and amphotericin. The subcuta-
neous fat was trimmed off and the cutis was cut and digested in
solution B containing 0.25% Trypsin (Pittelkow and Scott, 1986) at
4 1C for approximately 19 hours. The action of Trypsin was stopped
with solution A (Pittelkow and Scott, 1986), and the epidermis was
separated from the dermis using forceps. Fibroblasts were obtained
from dermal explants of human foreskin and cultured in DMEM with
10% FBS. Fibroblasts up to passage seven were used for organotypic
cultures.
Treatment of melanoma cells with signaling pathway inhibitors
and chemotherapeutic agents
The signaling pathway inhibitors wortmannin (Sigma, Steinheim,
Germany), LY294002 (Cell Signaling Technology, Beverly, MA),
rapamycin (Sigma Aldrich Chemie GmbH, Steinheim, Germany),
sorafenib, PD98059 and U0126 (Cell Signaling Technology,
Beverly, MA), and the chemotherapeutic agents cisplatin (Gry-
Pharma, Kirchzarten, Germany) and temozolomide (Schering-
Plough, Kenilworth, NJ) alone or in combination were added
directly to the culture medium of melanoma cells in monolayer or
organotypic culture of human dermis at concentrations previously
shown to be effective in single agent experiments. Melanoma cells
treated with culture medium or culture medium with the addition of
DMSO served as controls.
RNA interference
Cells were seeded at 3 105 cells per well the day before
transfection. Cells were transfected in 1ml of OPTIMEM (Invitrogen,
Karlsruhe, Germany) with 99 nM of BRAF-specific (50-AAGUGG
CAUGGUGAUGUGGCA-30; Wellbrock et al., 2004), or control
scrambled siRNA (50-AAGUCCAUGGUGACAGGAGAC-30; Well-
brock et al., 2004) using Lipofectamine 2000 (Invitrogen). After a 4-
hour incubation with the RNA complex, 2ml of medium containing
fetal calf serum were added. Cells were harvested 24 hours after the
transfection for further assays.
Western blot analyses
Melanoma cells were plated in six-well plates in culture medium at a
density of 125,000 cells per ml. After 48 hours, medium was
changed with medium containing the inhibitors and the chemother-
apeutics at test concentrations. Cells were washed with phosphate-
buffered saline (PBS) and lysed for 5minutes at room temperature
with 300ml Phosphosafe extraction reagent (Novagen, Darmstadt,
Germany) according to the manufacturer’s recommendations,
6–24 hours after treatment or 72 hours after transfection. Cell lysates
were cleared by centrifugation for 5minutes at 13.000 g at 4 1C
and 30 mg protein subjected to SDS–PAGE and transferred to
polyvinylidene difluoride membranes. After blocking in PBS/0.1%
Tween-20/5% dry milk for at least 1 hour, the blots were probed
overnight with primary antibodies in PBS/0.1% Tween-20/5% dry
milk, washed with PBS for 3 10minutes and incubated with
secondary biotin-conjugated antibody (Dako, Grostrup, Denmark).
After washing with PBS for 3 10minutes, the Streptavidin–Alk-
aline–Phosphatase conjugate (Roche, Mannheim, Germany) was
used for the detection of biotin-labeled secondary antibody. The
membrane was immersed in CDP-Star solution (Roche) for
10minutes and then exposed to X-ray film (Eastman Kodak,
Rochester, NY). The following primary antibodies were used: anti-
ERK, anti-phosho-ERK (Thr202/Tyr204), anti-AKT, anti-phospho-AKT
(Thr308), anti-phospho-p70S6K, anti-b-actin, anti-BRAF (Cell Signal-
ing Technology Inc.), anti-Bcl-2, anti-Bcl-xL, anti-Mcl-1 (BD
Biosciences Pharmingen, San Diego, CA).
Quantitative real-time PCR
Total RNA was extracted with the NucleoSpin RNA II Kit (Macherey-
Nagel, Du¨ren, Germany) and reverse transcribed with the Super-
script II Reverse Transcriptase (Invitrogen). Real-time PCR reactions
were performed in 20 ml mixtures using 1 SYBR Green PCR Master
Mix (BioRad, Mu¨nchen, Germany), 5 pmol of forward, 5 pmol of
reverse primer, and 2ml of cDNA sample. The Mcl-1 forward
50-GGACATCAAAAACGAAGACG-30 and reverse 50-GCAGCTTTC
TGGTTTTATGG-30 primers were used to yield a 154 bp amplificon,
whereas actin forward 50-TTGTTACAGGAAGTCCCTTGCC-30 and
reverse 50-ATGCTATCACCTCCCCTGTGTG-30 gave a 101 bp PCR
product. Real-time reactions were run in triplicates on the iCycler IQ
(BioRad) using the following universal cycling conditions for all
amplicons: 3minutes at 95 1C followed by 40 cycles of 15 seconds at
95 1C, 20 seconds at 60 1C, 20 seconds at 72 1C. Relative quantifica-
tion of Mcl-1 expression was done using the 2 (DDCt) method with
actin as housekeeping gene.
Growth assay
Melanoma cells (451Lu, SKMel28, 1205Lu, WM852, SKMel19,
Mewo) were seeded as triplicates in 96-well plates at a
density of 1,500 cells per well in 150 ml medium (1 104 cells per
ml). After 24 hours, medium was replaced by medium containing the
signaling pathway inhibitors LY294002, wortmannin, rapamycin,
sorafenib, PD98059, or U0126 or/and the chemotherapeutic
agents cisplatin or temozolomide at the concentrations to be tested.
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Cells treated with culture medium without or with DMSO served as
controls. Assay was started following incubation for 72 hours.
Medium was discarded, each well was washed two times with
PBS (without Ca2þ and Mg2þ ) and 100ml of a solution containing
100mg 4-methylumbelliferyl heptanoate per ml PBS was added.
Plates were incubated at 37 1C for 1 hour and measured in a
Fluoroskan II (Labsystems, Helsinki, Finland), with an lem of 355 nm
and an lex of 460 nm. The intensity of fluorescence indicates the
number of viable cells in the wells (Zouboulis et al., 1991).
Cell-cycle analysis
Cells were treated with culture medium plus DMSO as control, the
PI3K inhibitor LY294002 (30 mM), the mTOR inhibitor rapamycin
(10 nM), cisplatin (6mM), temozolomide (300mM), and combinations
of inhibitors with chemotherapeutics. After 72 hours, cells (1 106)
were harvested, washed with cold PBS, fixed with 75% ethanol, and
incubated at 4 1C for at least 1 hour. Cells were then centrifuged and
washed twice in cold PBS. Intracellular DNA was labeled with
propidium iodide solution (propidium iodide 40 mgml1 and RNase
100mgml1 in PBS) and incubated at 4 1C for 30minutes, in the
dark. Cell cycle was analyzed using flow cytometry and FACSDiva
software (BD Biosciences, Heidelberg, Germany). Results were
expressed as mean±SD values of three independent experiments.
Cell death detection ELISA
Internucleosomal DNA fragmentation was quantitatively assayed by
antibody-mediated capture and detection of cytoplasmic mono-
nucleosome- and oligonucleosome-associated histone-DNA com-
plexes (Cell Death Detection ELISA plus kit; Roche Molecular
Biochemicals, Mannheim, Germany) that accumulated in dying cells
with intact membrane. Briefly, cells (5,000 cells in 150ml medium in
96-well plates) were treated for 72 hours with culture medium
containing the inhibitors or/and the chemotherapeutic agents at the
concentrations to be tested or culture medium plus DMSO as
controls and lysed directly in the well with 200 ml buffer supplied by
the manufacturer for 30minutes at room temperature. After pelleting
nuclei (200 g, 10minutes), 20 ml of the supernatant (cytoplasmic
fraction) was used in the ELISA following the manufacturer’s
standard protocol. Finally, absorbance at 405 and 490nm (reference
wavelength), on incubating with a peroxidase substrate for
15minutes, was determined with a microplate reader (SLT; Spectra
LabInstruments, Crailsheim, Germany). The rate of apoptosis is
reflected by the enrichment (fold increase) of mono- and oligonu-
cleosomes accumulated in the cytoplasm and was calculated
according to the formula: absorbance of sample cells/absorbance
of control cells. Results were expressed as mean±SD values of
triplicates from two independent experiments.
Organotypic culture of human melanoma
The technique of in vitro reconstruction of human melanoma was
utilized to study invasive growth (Meier et al., 2000). A buffered
collagen solution was prepared consisting of rat tail collagen type I
(BD Biosciences, Bedford, MA) at a final concentration of
1.35mgml1 in DMEM with 10% FBS. A portion of 1.0ml of the
collagen solution was added to tissue culture inserts (Millicell PC;
Millipore, Bedford, MA) placed in six-well tissue culture plates. A
second collagen solution was prepared, similar to the first, with the
addition of human fibroblasts and 451Lu human metastatic
melanoma cells. Fibroblasts and melanoma cells from subconfluent
cultures were trypsinised, washed, and resuspended in the second
collagen solution at a density of 1.5 106 per ml and a fibroblast to
melanoma cell ratio of 1:1. Cellular collagen solution (3.0ml) were
placed over the solidified acellular collagen layer. After 5 days of
incubation at 37 1C, the fibroblast contraction force causes the
collagen gel to contract. This structure represents the reconstructed
melanoma. For submerged culture conditions, 3ml of melanoma
cell culture medium supplemented with 10% FBS were added
beneath the insert and 2ml inside the insert. The culture medium
was changed every two days. After 14 days of submerged culture,
the melanoma reconstructs were harvested. Melanoma reconstructs
were fixed with 4% formaldehyde for 8–9 hours, dehydrated, and
embedded in paraffin. For routine light microscopy, paraffin sections
were stained with hematoxylin.
To test the efficacy of inhibitors and chemotherapeutics alone or
in combination against invasive melanoma growth, 451Lu metastatic
melanoma cells incorporated into human dermal reconstructs were
treated with culture medium plus DMSO as controls, the PI3K
inhibitor LY294002 (30 mM), the mTOR inhibitor rapamycin (10 nM),
cisplatin (3–6mM), temozolomide (300–500 mM), and combinations of
inhibitors with chemotherapeutics. 451Lu cells incorporated into
dermal reconstructs and treated with culture medium or culture
medium with the addition of DMSO served as controls. Paraffin
sections of inhibitor- or/and chemotherapeutic-treated melanoma
reconstructs and control-treated melanoma reconstructs were
stained with hematoxylin for assessment of invasive tumor growth
by routine light microscopy.
Data analysis
Statistical analyses were performed with a two-tailed unpaired t-test.
P-values o0.05 were considered statistically significant.
Response surface analysis of melanoma cells treated with
combinations of AKT pathway inhibitors and chemotherapeutic
agents was performed as previously described (Tallarida, 2000).
Briefly, the effects of drug combinations (z axis) were plotted against
the concentrations of the single drugs (x-, y axes). The surface
representing additive effects was developed with the dose-response
data curve fitted to the hyperbolic equation: effect¼ (maximal
effect concentration)/(maximal effectþ concenctration of half-
maximal effect).
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